OA is the most common degenerative joint disease. Its initial symptoms include loss of articular cartilage followed by progressive to joint stiffness, swelling, pain, and loss of mobility.
Stem cells are the body's raw materials cells from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. These daughter cells either become new stem cells (self-renewal) or become specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells or bone cells. No other cell in the body has the natural ability to generate new cell types.
Most stem cells used for the experimental treatment of OA are adult MSCs. Researchers can easily collect them from fat or bone marrow. MSCs are able to turn into cartilage, bone, muscle, tendon, ligaments, or fat, depending on the type of tissue that surrounds them. This is why researchers are studying MSCs in stem cell treatments for OA.
- Table of Contents
- List of Tables & Figures
- Charts
- Research Methodology
Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-stem-cell-therapy-for-osteoarthritis-2022-2028-224
This report contains market size and forecasts of Stem Cell Therapy for Osteoarthritis in Global, including the following market information:
Global Stem Cell Therapy for Osteoarthritis Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Stem Cell Therapy for Osteoarthritis market was valued at 23 million in 2021 and is projected to reach US$ 102.2 million by 2028, at a CAGR of 24.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Allogeneic Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Stem Cell Therapy for Osteoarthritis include Medipost, Nature Cell, Theracell Advanced Biotechnology and Takeda (TiGenix), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Stem Cell Therapy for Osteoarthritis companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment: Global Stem Cell Therapy for Osteoarthritis Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Stem Cell Therapy for Osteoarthritis Market Segment Percentages, by Type, 2021 (%)
- Allogeneic
- Autologous
Global Stem Cell Therapy for Osteoarthritis Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Stem Cell Therapy for Osteoarthritis Market Segment Percentages, by Application, 2021 (%)
- Primary Osteoarthritis
- Secondary Osteoarthritis
Global Stem Cell Therapy for Osteoarthritis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Stem Cell Therapy for Osteoarthritis Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Stem Cell Therapy for Osteoarthritis revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Stem Cell Therapy for Osteoarthritis revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Medipost
- Nature Cell
- Theracell Advanced Biotechnology
- Takeda (TiGenix)
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports
